Search research articles
Contact Us
Filters
Showing results (151-160 of 184) with videos related to
Page
of 19
Sort By:
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Future Oncology (London, England)
|
October 15, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Thomas Powles, Aarti Bhatia, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Kevin J Harrington, Barbara Burtness, Richard Greil, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 21, 2022
Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood
David C Qian, Bryan C Ulrich, Gang Peng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2021
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)
Robert L Ferris, Yael Flamand, Gregory S Weinstein, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 31, 2023
Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors
Travis P Schrank, Aditi Kothari, William H Weir, et al.
Future Oncology (London, England)
|
June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer
Barbara Burtness, Yael Flamand, Harry Quon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q M Chow, Robert Haddad, Shilpa Gupta, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 184) with videos related to
Sort By:
Page
of 19
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Future Oncology (London, England)
|
October 15, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Thomas Powles, Aarti Bhatia, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Kevin J Harrington, Barbara Burtness, Richard Greil, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 21, 2022
Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood
David C Qian, Bryan C Ulrich, Gang Peng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2021
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)
Robert L Ferris, Yael Flamand, Gregory S Weinstein, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 31, 2023
Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors
Travis P Schrank, Aditi Kothari, William H Weir, et al.
Future Oncology (London, England)
|
June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer
Barbara Burtness, Yael Flamand, Harry Quon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q M Chow, Robert Haddad, Shilpa Gupta, et al.
Page
of 19